Comparison of the prognostic value of different inflammation-based scores in patients with hepatocellular carcinoma after Lenvatinib therapy

Table 4 Baseline characteristics of patients grouped by prognostic nutritional index, n (%)

Variables	PNI ≤ 49.1 (n = 71)	PNI > 49.1 (n = 73)	P value
Age, year	54 (29-74)	50 (21-75)	0.018
Gender (male/female)	64/7 (90.1/9.9)	62/11 (84.9/15.1)	0.345
Hepatitis (yes/no)	58/13 (81.7/18.3)	54/19 (74.0/26.0)	0.265
ALT, U/L	48.1 (10-177.1)	42.9 (0.5-320.3)	0.248
AST, U/L	73.1 (27.1-506.7)	69.6 (21.8-290.5)	0.002
ALB, g/L	37.7 (28.3-46.4)	43.9 (35.2-50.9)	< 0.001
TBIL, µmol/L	17.2 (5.3-60.9)	15.8 (5.5-31.1)	0.068
Largest tumor size, cm	12.4 (2.8-23.1)	10.4 (1.2-21.5)	0.003
Tumor number (> 1/1)	59/12 (83.1/16.9)	50/23 (68.5/31.5)	0.041
Macrovascular invasion (yes/no)	56/15 (78.9/21.1)	46/27 (63.0/37.0)	0.036
Lymph node metastasis (yes/no)	18/53 (25.4/74.6)	21/52 (28.8/71.2)	0.645
TNM stage (III-IV/II)	64/7 (90.1/9.9)	61/12 (83.6/16.4)	0.243
Best tumor response
CR	0 (0)	0 (0)
PR	19 (26.8)	26 (35.6)
SD	34 (47.9)	33 (45.2)
PD	18 (25.4)	14 (19.2)
ORR	19 (26.8)	26 (35.6)	0.252
DCR	53 (74.6)	59 (80.8)	0.373

Values are presented as median (range). P < 0.05 is statistically significant. PNI: Prognostic nutritional index; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALB: Albumin; TBIL: Total bilirubin; TNM: Tumor-node-metastasis; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; ORR: Objective response rate; DCR: Disease control rate.